PALI
USDPalisade Bio Inc. Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$1.910
High
$1.970
Low
$1.822
Volume
1.22M
Company Fundamentals
Market Cap
259.3M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
8.45M
Exchange
NCM
Currency
USD
52-Week Range
Related News
Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations
Seasoned Pharmaceutical leader bringing over 24 years of experience in clinical development across autoimmune, metabolic, cardiovascular, and gastrointestinal indications Company remains focused on advancing PALI-2108
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn's disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical needs Carlsbad, CA,
Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio", or the "Company"), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.